Evidence map›Paper›PMID 28859868›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2018

Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease.

Louise China, Alexander Maini, Simon S Skene, Zainib Shabir, Yvonne Sylvestre, Romain A Colas, Lucy Ly, Natalia Becares Salles, Vittorio Belloti, Jesmond Dalli and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Review
  3. Albumin Restores Endothelial Cell Mitochondrial Morphology in Patients With Decompensated Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  4. Review
  5. Article
  6. Mechanisms of immunity in acutely decompensated cirrhosis and acute-on-chronic liver failure.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  7. Article
  8. [Interventional studies on acute-on-chronic liver failure: challenges and opportunities].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  9. The Impact of Liver Failure on the Immune System.International journal of molecular sciences · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. [Advances in the diagnosis, treatment, and prognosis of acute decompensatory cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Louise ChinaDivision of Medicine, University College London, London, United Kingdom. Electronic address: l.china@ucl.ac.uk.
Alexander MainiDivision of Medicine, University College London, London, United Kingdom.
Simon S SkeneUniversity of London Comprehensive Clinical Trials Unit, London, United Kingdom.
Zainib ShabirUniversity of London Comprehensive Clinical Trials Unit, London, United Kingdom.
Yvonne SylvestreUniversity of London Comprehensive Clinical Trials Unit, London, United Kingdom.
Romain A ColasBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Lucy LyBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Natalia Becares SallesDivision of Medicine, University College London, London, United Kingdom.
Vittorio BellotiDivision of Medicine, University College London, London, United Kingdom.
Jesmond DalliBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Derek W GilroyDivision of Medicine, University College London, London, United Kingdom.
Alastair O'BrienDivision of Medicine, University College London, London, United Kingdom.
University College London · GBQueen Mary University of London · GBUniversity of London · GBThe London College · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsPatients with acute decompensation and acute-on-chronic liver failure (AD/ACLF) have immune dysfunction, which increases their risk for infections; however, there are no effective treatments to restore their immune function. We investigated whether the potentially immune-restorative effects of albumin are mediated by its effects on prostaglandin E

methodsWe analyzed bloods samples from 45 of 79 patients with AD/ACLF and serum levels of albumin less than 30 g/L for whom infusion of 20% human albumin solution (HAS) increased serum levels of albumin 30 g/L or more in a feasibility study of effects of 20% HAS. Immune function was determined by comparison of macrophage function following addition of plasma samples. We also used samples from 12 healthy individuals. We measured binding of plasma proteins to PGE

resultsAt baseline, AD/ACLF patient plasma induced significantly lower production of tumor necrosis factor by healthy macrophages than plasma from healthy individuals (P < .0001). Plasma from patients after HAS infusion induced significantly higher levels of tumor necrosis factor production by macrophages (19.5 ± 4.8 ng/mL) compared with plasma collected before treatment (17.7 ± 4.5 ng/mL; P = .0013). There was a significantly lower proportion of plasma protein (albumin) binding to PGE

conclusionsAnalysis of blood samples from patients with AD/ACLF participating in a feasibility study of 20% HAS infusions has shown that infusions to raise serum albumin above 30 g/L reversed plasma-mediated immune dysfunction by binding and inactivating PGE

Indexed as

AdultAgedBlood Chemical AnalysisCytokinesDinoprostoneFemaleHumansImmunologic FactorsInfusions, IntravenousLiver FailureMaleMiddle AgedOpportunistic InfectionsSerumSerum Albumin, HumanCytokinesDinoprostoneImmunologic FactorsSerum Albumin, HumanALDATTIRE TrialImmune RegulationResolution Phase Lipid Mediators

Identifiers

PMID28859868
PMCPMC6168974
OpenAlexW2752211585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.